title: Clinical role of the mixed cell agglutination test in the prospective management of superficial bladder tumors.
abstract: The mixed cell agglutination test allows the selection of patients with transitional cell carcinoma of the bladder who are at risk to develop invasive disease. A review of our retrospective experience and that of others reveals an overall accuracy of 78% in the prediction of tumor behavior. Current prospective studies are described and a rational, selective approach to the follow-up of bladder tumor patients, influenced by the MCA test result, is advocated.
mesh_terms: D000951:Antigens, Neoplasm / Q000032:analysis; D002295:Carcinoma, Transitional Cell / Q000276:immunology*; D006384:Hemagglutination; D006801:Humans; D007158:Immunologic Techniques; D009361:Neoplasm Invasiveness; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm